Cargando…

Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes

OBJECTIVE: The prevalence and clinical impact on mortality of carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection are unclear in elderly patients. Here, we aimed to clarify the prevalence, the clinical manifestations, antimicrobial resistance, risk factors and outcomes of elderly inpatients...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Jie, Zou, Chengyun, Tao, Jianmin, Wei, Tian, Yan, Li, Zhang, Yufei, Wang, Haiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064054/
https://www.ncbi.nlm.nih.gov/pubmed/35517901
http://dx.doi.org/10.2147/IDR.S358778
_version_ 1784699284664352768
author Qin, Jie
Zou, Chengyun
Tao, Jianmin
Wei, Tian
Yan, Li
Zhang, Yufei
Wang, Haiying
author_facet Qin, Jie
Zou, Chengyun
Tao, Jianmin
Wei, Tian
Yan, Li
Zhang, Yufei
Wang, Haiying
author_sort Qin, Jie
collection PubMed
description OBJECTIVE: The prevalence and clinical impact on mortality of carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection are unclear in elderly patients. Here, we aimed to clarify the prevalence, the clinical manifestations, antimicrobial resistance, risk factors and outcomes of elderly inpatients with CRPA infection. METHODS: A retrospective study of 600 elderly inpatients infected with P. aeruginosa was conducted at Yueyang Hospital of Integrated Traditional Chinese and Western Medicine from January 1st 2018 to December 31st 2020. All 155 patients with CRPA infection were designated as a case group. Patients with carbapenem-susceptible Pseudomonas aeruginosa (CSPA) were randomly selected from remaining 445 cases in a 1:1 ratio to case group as a control group. RESULTS: Of 600 P. aeruginosa isolates, the overall rates of CRPA, MDR PA (multidrug-resistance Pseudomonas aeruginosa) were 25.8% (155), 22.3% (134), respectively. The rankings of the top five resistant rates of CRPA to tested antimicrobial drugs were imipenem (87.7%), meropenem (70.3%), ciprofloxacin (51.0%), levofloxacin (48.4%), cefoperazone (43.2%). Independent risk factors for patients with CRPA infection were cerebrovascular disease (OR = 3.517, P < 0.001), foley catheter (OR = 2.073, P = 0.018), length of hospital stay ≥ 14 days (OR = 1.980, P = 0.013), albumin < 35 g/L (OR = 2.049, P = 0.020), previous antibiotic exposure to carbapenems (OR = 7.022, P = 0.004), previous antibiotic exposure to third- or fourth-generation cephalosporins (OR = 12.649, P = 0.002). Of 155 patients with CRPA infection, the mortality rate was 16.8% (26/155). Independent risk factors for mortality were receiving mechanical ventilation (OR = 3.671, P = 0.007) and neutrophil percentage ≥ 80% (OR = 2.908, P = 0.024). CONCLUSION: The study revealed high rates of CRPA, MDR PA among the hospitalized elderly patient with P. aeruginosa infection. The analysis of antimicrobial susceptibility emphasizes the necessity for antimicrobial stewardship and infection control in hospitals. These findings of risk factors are practical significant to identify patients at high risk for CRPA infection and mortality that may benefit from alternate empiric treatment.
format Online
Article
Text
id pubmed-9064054
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90640542022-05-04 Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes Qin, Jie Zou, Chengyun Tao, Jianmin Wei, Tian Yan, Li Zhang, Yufei Wang, Haiying Infect Drug Resist Original Research OBJECTIVE: The prevalence and clinical impact on mortality of carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection are unclear in elderly patients. Here, we aimed to clarify the prevalence, the clinical manifestations, antimicrobial resistance, risk factors and outcomes of elderly inpatients with CRPA infection. METHODS: A retrospective study of 600 elderly inpatients infected with P. aeruginosa was conducted at Yueyang Hospital of Integrated Traditional Chinese and Western Medicine from January 1st 2018 to December 31st 2020. All 155 patients with CRPA infection were designated as a case group. Patients with carbapenem-susceptible Pseudomonas aeruginosa (CSPA) were randomly selected from remaining 445 cases in a 1:1 ratio to case group as a control group. RESULTS: Of 600 P. aeruginosa isolates, the overall rates of CRPA, MDR PA (multidrug-resistance Pseudomonas aeruginosa) were 25.8% (155), 22.3% (134), respectively. The rankings of the top five resistant rates of CRPA to tested antimicrobial drugs were imipenem (87.7%), meropenem (70.3%), ciprofloxacin (51.0%), levofloxacin (48.4%), cefoperazone (43.2%). Independent risk factors for patients with CRPA infection were cerebrovascular disease (OR = 3.517, P < 0.001), foley catheter (OR = 2.073, P = 0.018), length of hospital stay ≥ 14 days (OR = 1.980, P = 0.013), albumin < 35 g/L (OR = 2.049, P = 0.020), previous antibiotic exposure to carbapenems (OR = 7.022, P = 0.004), previous antibiotic exposure to third- or fourth-generation cephalosporins (OR = 12.649, P = 0.002). Of 155 patients with CRPA infection, the mortality rate was 16.8% (26/155). Independent risk factors for mortality were receiving mechanical ventilation (OR = 3.671, P = 0.007) and neutrophil percentage ≥ 80% (OR = 2.908, P = 0.024). CONCLUSION: The study revealed high rates of CRPA, MDR PA among the hospitalized elderly patient with P. aeruginosa infection. The analysis of antimicrobial susceptibility emphasizes the necessity for antimicrobial stewardship and infection control in hospitals. These findings of risk factors are practical significant to identify patients at high risk for CRPA infection and mortality that may benefit from alternate empiric treatment. Dove 2022-04-29 /pmc/articles/PMC9064054/ /pubmed/35517901 http://dx.doi.org/10.2147/IDR.S358778 Text en © 2022 Qin et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Qin, Jie
Zou, Chengyun
Tao, Jianmin
Wei, Tian
Yan, Li
Zhang, Yufei
Wang, Haiying
Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes
title Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes
title_full Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes
title_fullStr Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes
title_full_unstemmed Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes
title_short Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes
title_sort carbapenem resistant pseudomonas aeruginosa infections in elderly patients: antimicrobial resistance profiles, risk factors and impact on clinical outcomes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064054/
https://www.ncbi.nlm.nih.gov/pubmed/35517901
http://dx.doi.org/10.2147/IDR.S358778
work_keys_str_mv AT qinjie carbapenemresistantpseudomonasaeruginosainfectionsinelderlypatientsantimicrobialresistanceprofilesriskfactorsandimpactonclinicaloutcomes
AT zouchengyun carbapenemresistantpseudomonasaeruginosainfectionsinelderlypatientsantimicrobialresistanceprofilesriskfactorsandimpactonclinicaloutcomes
AT taojianmin carbapenemresistantpseudomonasaeruginosainfectionsinelderlypatientsantimicrobialresistanceprofilesriskfactorsandimpactonclinicaloutcomes
AT weitian carbapenemresistantpseudomonasaeruginosainfectionsinelderlypatientsantimicrobialresistanceprofilesriskfactorsandimpactonclinicaloutcomes
AT yanli carbapenemresistantpseudomonasaeruginosainfectionsinelderlypatientsantimicrobialresistanceprofilesriskfactorsandimpactonclinicaloutcomes
AT zhangyufei carbapenemresistantpseudomonasaeruginosainfectionsinelderlypatientsantimicrobialresistanceprofilesriskfactorsandimpactonclinicaloutcomes
AT wanghaiying carbapenemresistantpseudomonasaeruginosainfectionsinelderlypatientsantimicrobialresistanceprofilesriskfactorsandimpactonclinicaloutcomes